Evidence map›Paper›PMID 37534372›Full record

ArticleClinical pathology (Thousand Oaks, Ventura County, Calif.)

OSNA Total Tumor Load for the Prediction of Axillary Involvement in Breast Cancer Patients: Should We use Different Thresholds According to the Intrinsic Molecular Subtype? MOTTO Study.

L Bernet, D Hardisson, M Rodrigo, A Córdoba, M Sancho, V Peg, I Ruiz, F Godey, J I Sánchez-Méndez, A Prat

Open access · goldAbstract read
In one paragraph

Article in Clinical pathology (Thousand Oaks, Ventura County, Calif.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

L BernetDepartment of Pathology, Hospital Universitario del Vinalopó, Elche, Spain.
D HardissonDepartment of Pathology, Hospital Universitario La Paz, Madrid.
M RodrigoDepartment of Pathology, Hospital Universitario de Burgos, Burgos, Spain.
A CórdobaDepartment of Pathology, Hospital Universitario de Navarra, Navarra, Spain.
M SanchoDepartment of Pathology, Hospital Universitario de Salamanca, Salamanca, Spain.
V PegDepartment of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.
I RuizDepartment of Pathology, Hospital Universitario de Donostia, Donostia, Spain.
F GodeyDepartment of Pathology, Centre Eugène Marquis, Rennes, France.
J I Sánchez-MéndezDepartment of Ginecology and Obstetrics, Hospital Universitario La Paz, Madrid.
A PratMedical Oncology department, Hospital Clínic de Barcelona, Barcelona, Spain.
Centre Eugène Marquis · FRComplejo Hospitalario de Salamanca · ESDonostia Unibertsitate Ospitalea · ESHospital Clínic de Barcelona · ESHospital Universitario de Burgos · ESHospital Universitario del Vinalopó · ESHospital Universitario La Paz · ESUniversidad Autónoma de Madrid · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To assess the impact of the molecular subtype (MS) on the total number of CK19 mRNA copies in all positive SLN (TTL) threshold, to predict non-SLN affectation, and to compare 5 years progression-free survival (PFS) according to the risk of recurrence (ROR) group by PAM50. Methods: Cohort with infiltrating breast cancer with intra-operative metastatic SLN detected by one-step nucleic acid amplification (OSNA) assay who underwent subsequent ALND. Logistic regression was used to assess a possible interaction between TTL and MS(Triple Negative, Her-2-Enriched, Luminal A, or Luminal B), or hormone receptors (HR: positive or negative) by immunohistochemistry (IMH). Cox regression was used to compare PFS and OS in the 3 ROR groups (high, medium, or low). Results: TTL was predictive of non-SLN affectation in both univariate (OR [95% CI]: 1.72 [1.43, 2.05], Conclusions: our results do not provide evidence to support the utilization of subtype-specific thresholds for TTL values to make therapeutic decisions on the axilla. The ROR group was predictive of 5 years-PFS.

Indexed as

Breast cancermolecular subtypetotal Tumor load

Identifiers

PMID37534372
PMCPMC10392164
OpenAlexW4385469519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.